Skip to main content

Table 3 Association of combined expression status of SIRT1 and N1IC with clinicopathological parameters

From: Correlation and prognostic value of SIRT1 and Notch1 signaling in breast cancer

Characteristics N SIRT1/N1IC
   High/low Low/low High/high Low/high χ 2 p- value
   N (%) N (%) N (%) N (%)   
Age (years)        
   <50 74 12 (16.2) 1 (1.4) 44 (59.4) 17 (23.0) 6.027 0.110
  ≥50 76 22 (28.9) 4 (5.3) 37 (48.7) 13 (17.1)
Lymph node metastasis        
  Absence 83 18 (21.7) 4 (4.8) 48 (57.8) 13 (15.7) 3.664 0.300
  Presence 67 16 (23.9) 1 (1.5) 33 (49.3) 17 (25.4)
TNM stage        
  I-III 128 30 (23.4) 4 (3.1) 69 (53.9) 25 (19.5) 0.441 0.932
  IV 22 4 (18.2) 1 (4.5) 12 (54.5) 5 (22.7)
Histological grade        
  1 + 2 102 18 (17.6) 4 (3.9) 55 (53.9) 25 (24.5) 7.334 0.062
  3 48 16 (33.3) 1 (2.1) 26 (54.2) 5 (10.4)   
ER status        
  Negative 71 17 (23.9) 2 (2.8) 33 (46.5) 19 (26.8) 4.728 0.193
  Positive 79 17 (21.5) 3 (3.8) 48 (60.8) 11 (13.9)
PR status        
  Negative 71 17 (23.9) 2 (2.8) 36 (50.7) 16 (22.5) 0.910 0.823
  Positive 79 17 (21.5) 3 (3.8) 45 (57.0) 14 (17.7)
HER2 status        
  Negative 111 28 (25.2) 4 (3.6) 52 (46.8) 27 (24.3) 10.052 0.018*
  Positive 39 6 (15.4) 1 (2.6) 29 (74.4) 3 (7.7)
Adjuvant therapy        
  Chemo 75 17 (22.7) 2 (2.7) 43 (57.3) 13 (17.3) 17.431 0.042*
  Chemo + radio 15 2 (13.3) 1 (6.7) 7 (46.7) 5 (33.3)
  Chemo + radio + endocrine 12 2 (16.7) 1 (8.3) 2 (16.7) 7 (58.3)
  Unknown 48 13 (27.1) 1 (2.1) 29 (60.4) 5 (10.4)
  1. Chemo: chemotherapy; Radio: radiotherapy; Endo: endocrine therapy; N: number of patients; *P < 0.05.